Abstract
Summary
In our systematic review and meta-analysis, we comprehensively evaluated menatetrenone in the management of osteoporosis. We found that menatetrenone decreased the ratio of undercarboxylated osteocalcin to osteocalcin (ucOC/OC) and improved lumbar BMD compared with placebo based on the 18 studies assessed. However, its benefit in fracture risk control was uncertain.
Introduction
We performed a systematic review and meta-analysis of the efficacy and safety of menatetrenone in managing osteoporosis.
Methods
PubMed, Cochrane Library, Embase, ClinicalTrials.gov, and three Chinese literature databases (CNKI, CBM, Wanfang) were searched for relevant randomized controlled trials (RCTs) published before October 5, 2017, comparing menatetrenone with other anti-osteoporotic drugs or placebo in treating osteoporosis. The pooled risk ratio (RR) or mean difference (MD) and 95% confidence interval (CI) were calculated using fixed-effects or random-effects meta-analysis.
Results
Eighteen RCTs (8882 patients) were included. Pooled analyses showed that menatetrenone was more effective than placebo in improving lumbar bone mineral density (BMD) (five studies, N = 658, MD = 0.05 g/cm2, 95% CI 0.01 to 0.09 g/cm2) and decreasing ucOC/OC (two studies, N = 75, MD = − 21.78%, 95% CI − 33.68 to − 9.87%). Compared with placebo, menatetrenone was associated with a nonsignificantly decreased risk of vertebral fracture (five studies, N = 5508, RR = 0.87, 95% CI 0.64 to 1.20). Evidence on other anti-osteoporotic drugs as comparators was limited and revealed no significantly different effects of menatetrenone on BMD or fracture risks. Furthermore, compared with placebo, menatetrenone significantly increased the incidence of adverse events (AEs) (two studies, N = 1949, RR = 1.47, 95% CI 1.07 to 2.02) and adverse drug reactions (four studies, N = 6102, RR = 1.29, 95% CI 1.07 to 1.56). However, no significant difference in the incidence of serious AEs was found between menatetrenone and placebo.
Conclusions
Menatetrenone significantly decreases ucOC and might improve lumbar BMD in osteoporotic patients. However, its benefit in fracture risk control is uncertain.
Similar content being viewed by others
Change history
27 August 2021
A Correction to this paper has been published: https://doi.org/10.1007/s00198-021-06053-8
References
International Osteoporosis Foundation. https://www.iofbonehealth.org/what-osteoporosis-0. Accessed 1 May 2018
Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733. https://doi.org/10.1007/s00198-006-0172-4
Keene GS, Parker MJ, Pryor GA (1993) Mortality and morbidity after hip fractures. BMJ 307:1248–1250. https://doi.org/10.1136/bmj.307.6914.1248
Baim S (2017) The future of fracture risk assessment in the management of osteoporosis. J Clin Densitom 20:451–457. https://doi.org/10.1016/j.jocd.2017.06.015
Mithal A, Kaur P (2012) Osteoporosis in Asia: a call to action. Curr Osteoporos Rep 10:245–247. https://doi.org/10.1007/s11914-012-0114-3
Briggs AM, Cross MJ, Hoy DG, Sànchez-Riera L, Blyth FM, Woolf AD, March L (2016) Musculoskeletal health conditions represent a global threat to healthy aging: a report for the 2015 World Health Organization world report on aging and health. Gerontologist 56(Suppl 2):S243–S255. https://doi.org/10.1093/geront/gnw002
Delmas PD (2002) Treatment of postmenopausal osteoporosis. N Engl J Med 359:736–746
Hauschka PV, Lian JB, Cole DE, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990–1047
Urayama S, Kawakami A, Nakashima T, Tsuboi M, Yamasaki S, Hida A, Ichinose Y, Nakamura H, Ejima E, Aoyagi T (2000) Effect of vitamin K 2 on osteoblast apoptosis: vitamin K 2 inhibits apoptotic cell death of human osteoblasts induced by Fas, proteasome inhibitor, etoposide, and staurosporine. J Lab Clin Med 136:181–193
Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ (2006) Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med (Structured abstract) 166:1256–1261
Fang Y, Hu C, Tao X, Wan Y, Tao F (2012) Effect of vitamin K on bone mineral density: a meta-analysis of randomized controlled trials. J Bone Miner Metab 30:60–68. https://doi.org/10.1007/s00774-011-0287-3
Huang ZB, Wan SL, Lu YJ, Ning L, Liu C, Fan SW (2015) Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: a meta-analysis of randomized controlled trials. Osteoporos Int 26:1175–1186. https://doi.org/10.1007/s00198-014-2989-6
Iwamoto J (2014) Vitamin K(2) therapy for postmenopausal osteoporosis. Nutrients 6:1971–1980. https://doi.org/10.3390/nu6051971
Iwamoto J, Sato Y (2013) Menatetrenone for the treatment of osteoporosis. Expert Opin Pharmacother 14:449–458. https://doi.org/10.1517/14656566.2013.763796
Palermo A, Tuccinardi D, D’Onofrio L, Watanabe M, Maggi D, Maurizi AR, Greto V, Buzzetti R, Napoli N, Pozzilli P, Manfrini S (2017) Vitamin K and osteoporosis: myth or reality? Metabolism 70:57–71. https://doi.org/10.1016/j.metabol.2017.01.032
Stevenson M, Lloyd-Jones M, Papaioannou D (2009) Vitamin K to prevent fractures in older women: systematic review and economic evaluation. Health Technol Assess 13(iii-xi):1–134. https://doi.org/10.3310/hta13450
Higgins J, Green SE (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. http://handbook-5-1.cochrane.org/ Accessed 22 November 2017
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Epidemiol Biostat Public Health 6:e1–e34
Zhao JG, Zeng XT, Wang J, Liu L (2017) Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis. Jama 318:2466–2482
Steichen T (2001) METANINF: Stata module to evaluate influence of a single study in meta-analysis estimation. Stat Softw Components. http://ideas.repec.org/c/boc/bocode/s419201.html Accessed 4 Sept 2018
Orimo H, Shiraki M, Tomita A, Morii H, Fujita T, Ohata M (1998) Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: a double-blind placebo-controlled study. J Bone Miner Metab 16:106–112. https://doi.org/10.1007/s007740050034
Iwamoto J, Takeda T, Ichimura S (2000) Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis. J Orthop Sci 5:546–551
Orimo H, Fujita T, Onomura T, Inoue T, Kushida K, Shiraki M (1992) Clinical evaluation of Ea-0167 (menatetrenone) in the treatment of osteoporosis. Phase III double-blind multicenter comparative study with alfacalcidol. Clin Eval 20:45–100
Shiraki M, Shiraki Y, Aoki C, Miura M (2000) Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 15:515–521. https://doi.org/10.1359/jbmr.2000.15.3.515
Iwamoto J, Takeda T, Ichimura S (2001) Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. J Orthop Sci 6:487–492. https://doi.org/10.1007/s007760100002
Ushiroyama T, Ikeda A, Ueki M (2002) Effect of continuous combined therapy with vitamin K(2) and vitamin D(3) on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas 41:211–221
Miki T, Nakatsuka K, Naka H, Kitatani K, Saito S, Masaki H, Tomiyoshi Y, Morii H, Nishizawa Y (2003) Vitamin K(2) (menaquinone 4) reduces serum undercarboxylated osteocalcin level as early as 2 weeks in elderly women with established osteoporosis. J Bone Miner Metab 21:161–165. https://doi.org/10.1007/s007740300025
Ishida Y, Kawai S (2004) Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi Osteoporosis Prevention Study. Am J Med 117:549–555. https://doi.org/10.1016/j.amjmed.2004.05.019
Inoue T, Fujita T, Kishimoto H, Makino T, Nakamura T, Nakamura T, Sato T, Yamazaki K (2009) Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. J Bone Miner Metab 27:66–75. https://doi.org/10.1007/s00774-008-0008-8
Shiraki M, Itabashi A (2009) Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study. J Bone Miner Metab 27:333–340. https://doi.org/10.1007/s00774-008-0034-6
Kasukawa Y, Miyakoshi N, Ebina T, Aizawa T, Hongo M, Nozaka K, Ishikawa Y, Saito H, Chida S, Shimada Y (2014) Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. J Bone Miner Metab 32:290–297. https://doi.org/10.1007/s00774-013-0490-5
Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M (2017) Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. J Bone Miner Metab 35:385–395. https://doi.org/10.1007/s00774-016-0768-5
Jiang Y, Zhang ZL, Zhang ZL, Zhu HM, Wu YY, Cheng Q, Wu FL, Xing XP, Liu JL, Yu W, Meng XW (2014) Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial. Clin Interv Aging 9:121–127. https://doi.org/10.2147/cia.s54107
Liu L (2015) The efficacy of vitamin K2 in treating osteoporotic patients and its effects on patients’ coagulation function. Master thesis. Jilin University. http://cdmd.cnki.com.cn/Article/CDMD-10183-1015591169.htm. Accessed 20 October 2017
Hu H, You M, Ran J (2017) The efficacy and safety of menatetrenone soft capsules combined with Salmon calcitonin in the treatment of elderly osteoporosis. Chin J Osteoporos 23:643–646
Luo J, Nie G, Huang X, Yang S, Xin J (2017) The effect of menatetrenone soft capsules with Caltrate Din the treatment of osteoporosis and femoral intertrochanteric fracture and its effect on bone metabolism index. Anhui Med Pharm J 21:1101–1105
Zhuang H, Chen D, Xu M, Su Q, Dong T (2017) The effect of vitamin K2 on the prevention and treatment of postmenopausal osteoporosis and serum cathepsin K. Chin J Osteoporosis 23:627–630 and 651
Purwosunu Y, Muharram, Rachman IA, Reksoprodjo S, Sekizawa A (2006) Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia. J Obstet Gynaecol Res 32:230–234. https://doi.org/10.1111/j.1447-0756.2006.00386.x
Vermeer C, Jie KS, Knapen MH (1995) Role of vitamin K in bone metabolism. Annu Rev Nutr 15:1–22
Szulc P, Chapuy MC, Meunier PJ, Delmas PD (1996) Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 18:487–488. https://doi.org/10.1016/8756-3282(96)00037-3
Shiraki M, Yamazaki Y, Shiraki Y, Hosoi T, Tsugawa N, Okano T (2010) High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment. J Bone Miner Metab 28:578–584. https://doi.org/10.1007/s00774-010-0167-2
Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11(Suppl 6):S2–S17
Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Bmj 312:1254–1259. https://doi.org/10.1136/bmj.312.7041.1254
Fujita Y, Iki M, Tamaki J, Kouda K, Yura A, Kadowaki E, Sato Y, Moon JS, Tomioka K, Okamoto N, Kurumatani N (2012) Association between vitamin K intake from fermented soybeans, natto, and bone mineral density in elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study. Osteoporos Int 23:705–714. https://doi.org/10.1007/s00198-011-1594-1
Yamauchi M, Yamaguchi T, Nawata K, Takaoka S, Sugimoto T (2010) Relationships between undercarboxylated osteocalcin and vitamin K intakes, bone turnover, and bone mineral density in healthy women. Clin Nutr 29:761–765. https://doi.org/10.1016/j.clnu.2010.02.010
Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK (2003) Bone loss and bone size after menopause. N Engl J Med 349:327–334
Confavreux CB (2011) Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int Suppl 79:S14–S19. https://doi.org/10.1038/ki.2011.25
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original online version of this article was revised: Corrections have been made in section "Results - Efficacy evaluations - Menatetrenone versus placebo/no additional drug", in Table 1, Figure 3 and in the Electronic Supplementary Material (ESM 3 and ESM 5).
Rights and permissions
About this article
Cite this article
Su, S., He, N., Men, P. et al. The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 30, 1175–1186 (2019). https://doi.org/10.1007/s00198-019-04853-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-019-04853-7